- Home
- AEON vs BRNS Comparison
AEON vs BRNS Comparison
Compare AEON & BRNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AEON | BRNS |
|---|---|---|
| Founded | N/A | 2016 |
| Country | United States | United States |
| Employees | 8 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.8M | 24.1M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | AEON | BRNS |
|---|---|---|
| Price | $0.92 | $0.69 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $7.20 | $4.00 |
| AVG Volume (30 Days) | ★ 122.6K | 16.9K |
| Earning Date | 05-14-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.43 | $0.51 |
| 52 Week High | $1.45 | $2.91 |
Technical Indicators
Market Signals| Indicator | AEON | BRNS |
|---|---|---|
| Relative Strength Index (RSI) | 42.62 | 54.61 |
| Support Level | $0.91 | $0.54 |
| Resistance Level | $1.12 | $0.76 |
| Average True Range (ATR) | 0.08 | 0.05 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 15.63 | 41.83 |
Price Performance
Historical ComparisonAbout AEON AEON Biopharma Inc.
AEON Biopharma Inc is a biopharmaceutical company focused on the development of ABP-450 (prabotulinumtoxinA), a biosimilar to Botox (onabotulinumtoxinA), for therapeutic indications. The company is advancing ABP-450 through the biosimilar regulatory pathway and holds development and commercialization rights across multiple international markets.
About BRNS Barinthus Biotherapeutics plc
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic drug candidates for treating autoimmune and inflammatory diseases. The company is prioritizing the development of its proprietary SNAP-TI platform, designed to promote immune tolerance, with its lead candidate VTP-1000 targeting celiac disease. It is also developing VTP-300 for chronic hepatitis B using viral vector platform technologies, aimed at inducing disease-specific immune responses.